RISPERDAL
RISPERDAL is approved FDA for treating bipolar disorders
FDA has approved RISPERDAL (resperidon) manufactured by the company both for monotherapy, and in combination with preparations of lithium or valry acid in short courses at acute maniacal or admixed attacks at bipolar alienations. Risperdal became the second atypical neuroleptic approved by FDA for application as a part of combined therapy of bipolar disorders (the first drug from this group has been approved in July, 2003 – it was Zyprex (olanzapine) manufactured by åðó company «Eli Lilly»). The decision to approve Risperdal was based on results of 3 clinical research of efficiency and safety of this preparation, in two of them analyzed its application as monotherapy, and in the third one its application in combination with preparations of lithium and valroy acid. In all researches the patients receiving Risperdal in dosage from 1 to 6 mg a day, noted significant improvement of indices estimated by YMRS (Young Mania Rating Scale) scale used for definition of maniacal symptoms expression degree. Risperdal in every used dosage was well tolerated, and a number of the patients who have stopped participation in research owing to formation of by-effects, was comparable to that in group receiving placebo. According to two researches where a course of Risperdal was prescribed as monotherapy, body weight increased by 7% and more from initial accordingly at 3.9 and 2,8 % of patients is noted. When performing the combined therapy this indicator made 10.5 %. Extrapyramidal disturbances, drowsiness, dyspepsia, nausea, disturbances of sight and hypersalivation were the most widespread by-effects at application of Risperdal as monotherapy. Usage of Risperdal as a part of combined therapy most often registered such collateral reactions, as drowsiness, giddiness,a parkinsonism, hypersalivation, akathisia, abdominal pain and urine incontience.
